Entrada Therapeutics Files 8-K

TL;DR

Entrada Therapeutics filed an 8-K on Feb 3, 2025. Standard reporting.

AI Summary

Entrada Therapeutics, Inc. filed an 8-K on February 3, 2025, reporting on other events and financial statements. The company, formerly known as CycloPorters, Inc., is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This filing provides an update on corporate events and financial reporting for Entrada Therapeutics, Inc., which is relevant for investors tracking the company's regulatory compliance and financial status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain significant new information that would immediately impact the company's risk profile.

Key Players & Entities

• Entrada Therapeutics, Inc. (company) — Registrant
• CycloPorters, Inc. (company) — Former company name
• February 3, 2025 (date) — Date of earliest event reported
• Boston, MA (location) — Principal executive offices
• 001-40969 (identifier) — Commission File Number

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share TRDA The Nasdaq Glo

Filing Documents

• trda-20250203.htm (8-K) — 35KB
• trda-202523xpr.htm (EX-99.1) — 16KB
• image_0a.jpg (GRAPHIC) — 10KB
• 0001689375-25-000002.txt ( ) — 201KB
• trda-20250203.xsd (EX-101.SCH) — 2KB
• trda-20250203_lab.xml (EX-101.LAB) — 23KB
• trda-20250203_pre.xml (EX-101.PRE) — 13KB
• trda-20250203_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 3, 2025, Entrada Therapeutics, Inc. (the "Company") issued a press release titled "Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy." A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On February 3, 2025, the Company announced the receipt of authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product for a Phase 1/2 multiple ascending dose clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy ("DMD") in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. ENTR-601-44 is Entrada's lead product candidate within its Duchenne franchise and is being developed for the potential treatment of individuals with Duchenne who are exon 44 skipping amenable.. The Phase 1/2 trial's primary objective is to evaluate the safety, tolerability and effectiveness of ENTR-601-44 in ambulatory patients with DMD who are exon 44 skipping amenable. The Company is on track to initiate the trial for ENTR-601-44 in the United Kingdom in the second quarter of 2025.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company's strategy, future operations, prospects and plans, objectives of management, expectations regarding the Company's planned Phase 1/2 multiple ascending dose clinical study ENTR-601-44, including its initiation in the United Kingdom in Q2 2025, the ability to recruit for and complete a Phase 1/2 clinical trial for ENTR-601-44, expectations regarding the safety and therapeutic benefits of ENTR-601-44, the continued development and advancement of ENTR-601-44 for the potential treatment of DMD, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical and clinical s

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit relating to Item 7.01 of this Form 8-K shall be deemed to be furnished and not filed: 99.1 Press Release issued by Entrada Therapeutics, Inc. on February 3 , 202 5 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entrada Therapeutics, Inc. Date: February 3, 2025 /s/ Dipal Doshi Dipal Doshi Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR